Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome

International Journal of Cancer

Volumn 104, Issue 6, 2003, Pages 728-734

  Korshunov, Andrey ^a   Shishkina, Lyudmila ^a   Golanov, Andrey ^a  

^a BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

Immunohistochemistry; Meningioma; p16INK4a; p18INK4c; p21CIP1; Recurrence

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; DNA DIRECTED DNA POLYMERASE ALPHA; PROTEIN; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P73; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER RECURRENCE; CELL CYCLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; ANTIGENS, NEOPLASM; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 0037431514     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11013     Document Type: Article

References (37)

1. Bruner JM, Tien RD, Enterline DS. Tumors of the meninges and related tissues. In: Bigner DD, McLendon RE, Bruner JM, eds. Russel and Rubinstein pathology of tumors of the nervous system, 6th ed. London: Arnold. 1998. 67-139.
2. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK, eds. Tumours of the nervous system; pathology and genetics: WHO International classification of tumours. Lyon: IARC Press, 2000. 176-84.
3. Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, Inai K. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1 and p27Kip1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 2001;32:970-5.
4. Hsu DW, Efird JT, Headley-White ET. MIB-1 (Ki-67) index and transforming growth factor-α (TGFα) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 1998;24:441-52.
5. Karamitopoulou E, Perentes E, Tolnay M, Probst A. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998;29:140-5.
6. Konstantinidou AE, Patsorius E, Korkolopoulou P, Kavantzas N, Mahera H, Davaris P. DNA topoisomerase IIα expression correlates with cell proliferation but not with recurrence in intracranial meningiomas. Histopathology 2001;39:402-8.
7. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberto N, Albanese V. Correlation between histological grade, MIB-1, p53 and recurrence in 69 completely resected primary intracranial meningiomas. Pathol Res Pract 2000;196:483-8.
8. Maier H, Wanaschitz, Sedivy R, Rossler K, Ofner D, Budka H. Proliferation and DNA fragmentation in meningioma subtypes. Neuropathol Appl Neurobiol 1997;23:496-506.
9. Nagashima C, Aoyagi M, Yamamoto M, Yamamoto S, Wakimoto H, Ohno K, Yamamoto K, Hirakawa K. p53 overexpression and proliferative potential in malignant meningiomas. Acta Neurochir 1999; 141:53-61.
10. Nakaguchi H, Fujimaki T, Matsuno A, Matsuura R, Asai A, Suzuki I, Sasaki T, Kirino T. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry. Cancer 1999; 85:2249-54.
11. Nakasu S, Li DH, Okabe H, Nakajima M, Matsuda M. Significance of MIB-1 staining indices in meningiomas: comparisons of two counting methods. Am J Surg Pathol 2001;25:472-8.
12. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53 and flow-cytometry in completely resected primary meningiomas. Cancer 1998;82:2262-9.
13. Abramovich CM, Prayson RA. Histopathological features and MIB-1 labeling indices in recurrent and non-recurrent meningiomas. Arch Pathol Lab Med 1999;123:793-800.
14. Møller ML, Braendstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry. J Neurooncol 1997;34:241-6.
15. Perry A, Cai DX, Scheithauer BW, Swanson P, Lohse CM, Newsham IF, Weaver A, Gutmann DH. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59:872-9.
16. Abramovich CM, Prayson RA. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome. Am J Clin Pathol 2000;114:84-92.
17. Hakin-Smith V, Battersby RD, Maltby EL, Timperley WR, Royds JA. Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence. Neuropathol Appl Neurobiol 2001;27:40-9.
18. Kamei Y, Watanabe M, Nakayama T, Kanamaru K, Waga S, Shiraishi T. Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micro necrosis for recurrence of meningiomas. J Neurooncol 2000;46:205-13.
19. Ohkoudo M, Sawa H, Hara M, Saruta K, Aiso T, Ohki R, Yamamoto H, Maemura R, Shiina Y, Fujii M, Saito I. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas. J Neurooncol 1998;38:41-9.
20. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001;58:1907-22.
21. Korshunov A, Shishkina L, Golanov A. DNA topoisomerase IIα and cyclin A immuno expression in meningiomas and its prognostic significance. An analysis of 263 cases. Arch Pathol Lab Med 2002; 126:1079-86.
22. Segal MR. Regression trees for censored data. Biometrics 1988;44: 35-47.
23. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinico-pathologic study of 116 patients with grading implication. Cancer 1999;85:2046-56.
24. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 1997;21:1455-65.
25. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P. Analysis of genomic alterations in benign, atypical and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997;94:14719-24.
26. Tse JY, Ng HK, Lo KW, Chong EY, Lam PY, NG EK, Poon WS, Huang DP. Analysis of cell cycle regulators: p16INK4A, pRb and CDK4 in low- and high-grade meningiomas. Hum Pathol 1998;29:1200-7.
27. Boström J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G. Alteration of the tumor suppressor genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b) and CDKN2C (p18INK4c) in atypical and anaplastic meningiomas. Am J Pathol 2001;159:661-9.
28. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 2002;12:183-90.
29. Leraud P, Marie Y, Robin E, Huguet S, He J, Mokhtari K, Cornu P, Hoang-Xuan K, Sanson M. Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas. J Neurooncol, 2000;50:207-13.
30. Mendiola M, Bello MJ, Alonso J, Leone PE, Vaquero J, Sarasa JL, Kusak ME, DeCampos JM, Pestana A, Rey JA. Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32. Mol Carcinog 1999;24:300-4.
31. Sanatrius T, Kirsch M, Nikas DC, Imitola J, Black PM. Molecular analysis of the p18INK4c gene in human meningiomas. Neuropathol Appl Neurobiol 2000;26:67-75.
32. Sulman EP, Dumanski JP, White PS, Zhao H, Maris JM, Mathiensen T, Bruder C, Cnaan A, Brodeur GM. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 1998;58:3226-30.
33. Hirai H, Roussel MF, Kato J-Y, Ashmun RA, Scherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-81.
34. Koopmann J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD, von Deimling A. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumors. Br J Cancer 1995;72: 1230-3.
35. Alonso ME, Bello MJ, Gonzales-Gomez P, Lomas J, Arjona D, de Campos JM, Kusak ME, Sarasa JL, Isla A, Rey JA. Mutation analysis of p73 gene in nonastrocytic brain tumors. Br J Cancer 2001;85: 204-8.
36. Lomas J, Bello MJ, Arjona D, Gonzalez-Gomez P, Alonso ME, de Campos JM, Vaquero J, Ruiz-Barnes P, Sarasa JL, Casartelli C, Rey JA. Analysis of p72 gene in meningiomas with deletion at 1p. Cancer Genet Cytogenet 2001;129:88-91.
37. Nozaki M, Tada M, Kashiwazaki H, Hamou MF, Diserens AK, Shinohe Y, Sawamura Y, Iwasaki Y, de Tribolet N, Hegi ME. p73 in not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. Brain Pathol 2001;11:296-305.